Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients: Updated phase II results and dose selection

ANNALS OF ONCOLOGY

ELSEVIER

1. G1 Therapeutics, Inc.